Affimed N.V. is a clinical-stage immuno-oncology company dedicated to providing patients with new hope in their fight against cancer by leveraging the untapped potential of the innate immune system. The company's proprietary Redirected Optimized Cell Killing (ROCK®) platform allows for the development of tumor-targeted immunotherapies that engage natural killer (NK) cells and macrophages to destroy tumor cells. Affimed is advancing a diverse pipeline of therapeutic candidates, both as monotherapies and in combination treatments, for various hematologic and solid tumors, aiming to make a significant impact on patient outcomes.
The Heidelberg facility is the nerve center for Affimed's research and development, clinical operations, and corporate management, driving the innovation and execution of its immuno-oncology programs.
Situated within the Heidelberg Technology Park, the headquarters benefits from state-of-the-art laboratory infrastructure, modern office spaces, and proximity to a vibrant ecosystem of academic institutions and biotech companies.
Affimed fosters a dynamic, collaborative, and science-driven work culture. Employees are united by a common mission to develop groundbreaking cancer therapies, with an emphasis on innovation, teamwork, and patient focus.
The Heidelberg headquarters is pivotal to Affimed's strategy, enabling cutting-edge research, efficient clinical trial management, and international collaborations necessary to advance its position as a leader in innate cell engager therapies.
Affimed's primary global functions, including research, development, and clinical trial oversight, are centralized at its operational headquarters in Heidelberg, Germany. The company's registered office is in Amsterdam, Netherlands. Affimed conducts clinical trials in multiple countries across North America and Europe, collaborating with international research institutions and contract research organizations to advance its therapeutic pipeline on a global scale.
Im Neuenheimer Feld 582
Heidelberg
Baden-Württemberg
Germany
Address: Strawinskylaan 4117, 1077 ZX Amsterdam
Maintains Affimed's legal domicile in the Netherlands, fulfilling statutory and regulatory obligations for a company incorporated and publicly listed under Dutch law.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Affimed' leadership includes:
Affimed has been backed by several prominent investors over the years, including:
Over the past year, Affimed N.V. experienced a significant transition in its executive leadership with the departure of its Chief Financial Officer and the subsequent appointment of a new CFO.
Discover the tools Affimed uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Affimed N.V. typically uses an email format consisting of the employee's first initial followed by a period and their full last name, then the @affimed.com domain. This is a standard professional email structure.
[first_initial].[last_name]@affimed.com
Format
d.mueller@affimed.com
Example
90%
Success rate
affimed.com • May 14, 2024
Affimed N.V. (Nasdaq: AFMD) announced its financial results for the first quarter ended March 31, 2024, and provided updates on its clinical programs, including progress with AFM24 and Acimtamig, and overall corporate strategy....more
affimed.com • April 2, 2024
Affimed N.V. shared final data from its AFM24 monotherapy study in EGFR wild-type non-small cell lung cancer (NSCLC) patients, along with initial data from the AFM24 combination trial with atezolizumab in various EGFR-mutant solid tumors, at the American Association for Cancer Research (AACR) Annual Meeting 2024....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Affimed, are just a search away.